stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) EBITDA
Ascendis Pharma A/S's EBITDA for fiscal 2025 was −$134.2M, compared with −$282.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $321.3M. Over the past ten years it has ranged from −$573.0M (fiscal 2022) to −$45.8M (fiscal 2015); the current reading is higher than 73% of that period. EBITDA has risen for 3 consecutive fiscal years. Ascendis Pharma A/S ranks 14th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$134.2M | — |
| FY2024 | −$282.5M | — |
| FY2023 | −$472.6M | — |
| FY2022 | −$573.0M | — |
| FY2021 | −$516.3M | — |
| FY2020 | −$366.9M | — |
| FY2019 | −$246.4M | — |
| FY2018 | −$181.7M | — |
| FY2017 | −$125.2M | — |
| FY2016 | −$79.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $261.6M | 669.93% |
| Mar 2026 | $34.0M | 333.34% |
| Dec 2025 | $7.8M | (56.07%) |
| Sep 2025 | $17.9M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| EXEL Exelixis, Inc. compare | $1.0B |
| HALO Halozyme Therapeutics, Inc. compare | $719.2M |
| ASND Ascendis Pharma A/S | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| INSM Insmed, Inc. compare | −$531.4M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ASND
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement